Efficacy and safety of immune checkpoint inhibitors combined with anti‑angiogenic agents for advanced cervical cancer: A systematic review and meta‑analysis
Combining anti‑angiogenic agents with immune checkpoint inhibitors (ICIs) may improve clinical outcomes in patients with advanced cervical cancer.
Combining anti‑angiogenic agents with immune checkpoint inhibitors (ICIs) may improve clinical outcomes in patients with advanced cervical cancer.
These findings suggest that adding anti‑angiogenic therapy to ICIs may enhance survival and maintain tolerable safety, offering a promising therapeutic option for patients with advanced cervical cancer.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- AI approach outperformed human experts in identifying cervical precancer